Arvinas (ARVN)
(Delayed Data from NSDQ)
$24.94 USD
-0.04 (-0.16%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $24.93 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 81 - 100 ( 210 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Cash Balance and 2022 Catalysts For Our Biotech Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
''471 Data Further Solidifies Pfizer''s Interest in Arvinas - Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471, a Potentially Best-in-Class Oral SERD Key Takeaways From the Phase 1 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471 Glistens in Ph 1 Dose-Escalation Data; Well Suited for Earlier Lines
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Companies With YE2021 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471 Data at SABCS Should Help Set Clear Expectations for 2022 Readouts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ?471 Program into High Gear in 2022; ?110 Data at ASCO-GU
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471 Readout Remains the Primary Focus; Reit Buy and $135 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update- Solid Programs & Pipeline With PT Boost Based on Pfizer Deal
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Poised to Build a Robust Prostrate Cancer Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Exciting Deal Likely to Accelerate Expanding Pipeline of PROTACs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R